Lyell Immunopharma, Inc. (LYEL) holder pays broker with 44,000 shares
Rhea-AI Filing Summary
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., transferred 44,000 shares of common stock to Wuxiong, Inc. as broker commission tied to a first Development Milestone under a license agreement. The transfer involved no cash consideration and is classified as an “other” disposition. After this transaction, the reporting holder beneficially owns 2,774,980 shares of Lyell common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 44,000 shares
Net Sell
1 txn
Insider
Innovative Cellular Therapeutics Holdings Ltd
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Common Stock F1, F2 | 44,000 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 2,774,980 shares (Direct)
Footnotes (2)
- F1. Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
- F2. Reflects 2,818,980 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 44,000 shares transferred.
Key Figures
Shares transferred: 44,000 shares of Common Stock
Shares beneficially owned after transaction: 2,774,980 shares of Common Stock
Shares beneficially owned before transaction: 2,818,980 shares of Common Stock
+3 more
6 metrics
Shares transferred
44,000 shares of Common Stock
Transferred on 2026-07-27 to Wuxiong, Inc. as broker commission
Shares beneficially owned after transaction
2,774,980 shares of Common Stock
Beneficial ownership of Innovative Cellular after the reported disposition
Shares beneficially owned before transaction
2,818,980 shares of Common Stock
Holdings immediately prior to transferring 44,000 shares as broker commission
Per-share transaction price
$0.0000 per share
Transfer of shares for no cash consideration to the reporting person
Transaction date
2026-07-27
Date of the “other” disposition reported on Form 4
License Agreement date
November 6, 2025
Date of License Agreement referenced for the first Development Milestone payment
Key Terms
Development Milestone, License Agreement, beneficially owned, broker commission
4 terms
Development Milestone financial
"in connection with the first Development Milestone payment"
License Agreement regulatory
"as defined in Section 6.2(a) of the License Agreement"
A license agreement is a contract where the owner of intellectual property, technology, a brand, or other rights gives another party permission to use those assets under specified conditions, usually for fees, royalties or other payments. For investors it matters because such deals create or limit predictable revenue streams, affect profit margins, transfer legal and commercial risk, and can determine how quickly a company can grow — like renting out a patented tool to earn steady income while keeping ownership.
beneficially owned financial
"Reflects 2,818,980 shares of Common Stock beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
broker commission financial
"transferred by the Reporting Person to Wuxiong, Inc. as broker commission"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did LYEL holder Innovative Cellular report?
Innovative Cellular Therapeutics Holdings Ltd reported an “other” disposition of 44,000 shares of Lyell Immunopharma common stock. The shares were transferred as broker commission connected to a first Development Milestone under a license agreement between Innovative Cellular and Lyell Immunopharma.
Was the LYEL insider transaction made under a Rule 10b5-1 trading plan?
The transaction was not reported as occurring under a Rule 10b5-1 trading plan. The Rule 10b5-1 affirmation box for the reporting person is not checked, indicating the disposition was not executed pursuant to a pre-arranged trading plan.
What agreement is linked to the LYEL insider’s broker commission transfer?
The broker commission transfer of 44,000 shares relates to the first Development Milestone payment under a License Agreement dated November 6, 2025. That agreement is between Lyell Immunopharma, Inc. and Innovative Cellular Therapeutics Holdings Ltd, the reporting ten-percent owner.